PubMed Health⌕ Search

Biomedical subjects

C Edouard

Publications and source records attributed to C Edouard.

At least 55 records · Page 3Linked to original sources
PubMed1980

Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.

After baseline studies, 21 patients with osteoporosis were treated with human parathyroid hormone fragment (PTH 1-34) given as once-daily subcutaneous injections for 6-24 months. The dose used did not cause hypercalcaemia even in the first few hours after injection. Calcium and phosphate balances improved in some patients, but there was no significant improvement in the group values. There were, however, substantial increases in iliac trabecular bone volume: the mean increase, confirmed by repeat blind measurements, was 70% above mean baseline volume. The new bone was histologically normal. Those patients who had the largest increases in 47Ca-kinetic and histomorphometric indices of new bone formation showed the greatest increases in trabecular bone volume, suggesting that treatment with human parathyroid hormone fragment caused a dissociation between formation and resorption rates that was confined to trabecular bone. Since vertebrae are four-fifths composed of trabecular bone, this hormone fragment may prove useful in treating patients with the crush fracture syndrome.

Aged↗
PubMed1980

[Histological effects of the treatment of osteoporosis with the combination of sodium fluoride, vitamin D and calcium].

A histomorphometric and dynamic study of non-decalcified transiliac biopsies was carried out in 51 cases of osteoporosis who had received double marking with tetracycline before and after two years treatment with association of sodium fluoride (50 mg/day) vitamin, D2 (8,000 IU/day) and calcium (1 g/day). The main effect of fluoride is an increase in the osteoblastic population, which is shown by an increase in the osteoid parameters. The osteoid volume is multiplied by 3,6, the osteoid surfaces by 2,4, and the index of osteoid thickness by 1,2. There exists a lesser increase in the reabsorption surfaces (X 1,2). There results a very significant increase in bony trabecular volume, the average value of which increase from 9,8 +/- 3,1% to 16,6 +/- 9.3% (X 1,8; p < 0.001). These results were found again both in apparently primary osteoporosis and in secondary osteoporosis. No significant depression was noted in the rate of calcification, but six patients developed a state of histological osteomalacia associated in 5 cases with an increased calcified volume. All these results are in good agreement with those of the world literature and indicate that fluoride is able in most cases (60%) to restore normal bones in osteoporosis with reduced risk of fracture.

Bone and Bones↗
PubMed1979

Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.

19 patients with Paget's disease were treated orally for 6 months with disodium dichloromethylene diphosphonate. 1600 mg/day (10 patients) significantly reduced urine hydroxyproline, serum alkaline phosphatase, urine calcium, and the number of pagetic bone osteoclasts. Tetracycline double labelling revealed undisturbed bone mineralisation. There was improvement on quantitative bone-scans and bone pain diminished. There was a transient increase in parathyroid hormone level in 13 of the 19 patients during treatment, which was associated with a high serum 1,25 (OH)2D3. No adverse clinical side-effects have been observed and biochemical remission has persisted for 9 months.

Administration, Oral↗
PubMed1975

[Clinical, biological and histological effects of ethane-1-hydroxy 1, 1-diphosphonate (EDHP) in Paget's disease].

The diphosphonates are analogues of the pyrophosphates that are capable of resisting enzymatic destruction and they become fixed in the bone tissue where they have a powerful inhibitory action on osteoclastic resorption and on osteoid mineralization. Ethane-1-hydroxy-1, 1-diphosphonate (EDHP) was administered by mouth at the dose of 20 mg/kg/day over a period of 3 to 6 months to 11 patients with painful Paget's disease. A marked analgesic effect was noted in 7 of the 11 patients. Spectacular metabolic effects were noted with return to normal of the total hydroxyprolinuria/24 h and of the alkaline phosphatases 3 months after treatment in 6 of the 11 treated subjects and a marked improvement in these parameters in 4 other patients. Histologically, there was almost total disappearance of osteoclasia and of osteoblastosis in the affected areas. Clinically, the secondary effects presented in some cases as diarrhoea, and an early and marked rise in phosphoraemia was recorded. Histologically, hyperosteoidosis was seen, equally in the affected and nonaffected zones. This resulted from an almost complete stoppage in the calcification of the osteoid as indicated by the double labelling by tetracycline. The review of the literature shows that considerable therapeutic effects are obtained even with very small doses of EHDP, e.g., 10 mg/kg/day for 3 months, but that these are often accompanied by more marked secondary effects. The diphosphonates appear to be a promising treatment for Paget's disease.

Alkaline Phosphatase↗